Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
A phase 2 trial of Busulfan, Gemcitabine, Melphalan and Panobinostat in Plasma cell leukaemia, run by M.D. Anderson Cancer Center, completed.
Overview
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma is a phase 2 interventional study registered as NCT02506959 by M.D. Anderson Cancer Center, with 83 participants recorded, started 2015-09-14 and reaching its primary completion in 2024-06-03. Interventions recorded: Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study. Conditions recorded: Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma.
Linked to the drug Panobinostat because the registry names it among its interventions and Plasma cell leukaemia among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialPhase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Shares Panobinostat and the tag pipeline.
- TrialEfficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Shares Panobinostat and the tag pipeline.
- TrialStudy Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Shares Busulfan and the tag pipeline.
- TrialHigh-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
Shares Busulfan, Melphalan (including hepatic delivery system) and the tag pipeline.
- TrialA Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Shares Melphalan (including hepatic delivery system) and the tag pipeline.
- TrialClinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Shares Busulfan and the tag pipeline.
- TrialPercutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Shares Melphalan (including hepatic delivery system) and the tag pipeline.
- TrialStudy to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Shares Panobinostat, Gemcitabine and the tag pipeline.